Nova TheraNostics (NTN) is commercializing a novel, biocompatible, lipid-nanoparticle carrier platform technology designed to address multiple medical applications, the first being an enhanced gadolinium-based MRI contrast agent. These gadolinium-containing lipid nanoparticles have several novel characteristics. First, they are roughly 33-fold more sensitive than commercially available gadolinium contrast agents. These particles stay completely (>99%) within the bloodstream, have a longer serum half-life, and are completely eliminated by 24 hours, which allows this agent to be used in blood pool (vascular) imaging applications. Finally, they are unique in that they are eliminated by the liver through the bile into the gut, and not eliminated through the kidneys as are other contrast agents, making it likely a much safer agent to administer in patients with renal disease. NTN's contrast agent is currently in preclinical testing and likely will be the first one available for safe use in the 26+ million Americans with acute and chronic kidney disease.
Company Details
- Employees
- 1
- Founded
- -
- Address
- 4311 11th Ave Ne, Seattle,98105,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- novatheranostics.com
- HQ
- Seattle
Nova Theranostics Llc Questions
Nova Theranostics Llc's website is novatheranostics.com
Nova Theranostics Llc's LinkedIn profile is https://www.linkedin.com/company/nova-theranostics-llc
Nova Theranostics Llc has
1 employees.
View email and phone details for 1
employees at Nova Theranostics Llc.
Nova Theranostics Llc's industry is
Biotechnology Research
Nova Theranostics Llc's top competitors are
Theranostics India,
Telix Pharmaceuticals Limited,
Radiopharm Theranostics,
Clarity Pharmaceuticals,
Healthcare Insight News,
Aviko Radiopharmaceuticals,
Theranostics,
United Theranostics.
Nova Theranostics Llc's categories are Biotechnology Research
Nova Theranostics Llc's founding year is 2010
